Use of the ketogenic diet to manage refractory epilepsy in CDKL 5 disorder: Experience of >100 patients
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Summary: Objective: Pathogenic variants involving the CDKL 5 gene result in a severe epileptic encephalopathy, often later presenting with features similar to Rett syndrome. Cardinal features of epilepsy in the CDKL5 disorder include early onset at a median age of 6 weeks and poor response to antiepileptic drugs. The ketogenic diet (KD) was first introduced in the 1920s as a treatment option for refractory epilepsy in children. This study investigated use of the KD in the CDKL5 disorder and its influences on seizures. Methods: The International CDKL 5 Disorder Database, established in 2012, collects information on individuals with the CDKL5 disorder. Families have provided information regarding seizure characteristics, use, and side effects of the KD treatment. Descriptive statistics and time to event analyses were performed. Clinical vignettes were also provided on patients attending Boston Children's Hospital. Results: Data regarding KD use were available for 204 individuals with a pathogenic CDKL 5 variant. Median age of inclusion in the database was 4.8 years (range = 0.3–33.9 years), with median age of 6 weeks (range = 1 day–65 weeks) at seizure onset. History of KD use was reported for 51% (104 of 204) of individuals, with a median duration of use of 17 months (95% confidence interval = 9–24). Changes in seizure activity after commencing KD were reported for two‐thirds (69 of 104), with improvements in 88% (61 of 69). Nearly one‐third (31.7%) experienced side effects during the diet. At ascertainment, only one‐third (32%) remained on the diet, with lack of long‐term efficacy as the main reason for diet cessation (51%, 36 of 70). Significance: Benefits of KD in the CDKL5 disorder are in keeping with previous trials on refractory epilepsies. However, poor long‐term efficacy remains as a significant barrier. In view of its side effect profile, KD administration should be supervised by a pediatric neurologist and specialist dietician.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticonvulsant Mechanisms of the Ketogenic Diet
Bough, K. J., & Rho, J. M. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00915.x · Cited by 523
Application of a ketogenic diet in children with autistic behavior: Pilot study
Evangeliou, A., Vlachonikolis, I., Mihailidou, H., Spilioti, M., Skarpalezou, A., Makaronas, N., Prokopiou, A., Christodoulou, P., Liapi-Adamidou, G., Helidonis, E., et al. (2003) · Journal of Child Neurology · doi:10.1177/08830738030180020501 · Cited by 279
The Ketogenic diet: from molecular mechanisms to clinical effects
(2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2005.10.003 · Cited by 213 · cited 1×
“However, the uncertainty regarding long-term efficacy and the significant side effect profile of the KD serve as major barriers against treatment maintenance.(17,18) We recently reported that, despite AED use, more than two-thirds of individuals with the CDKL5 disorder were having seizures once or more per day, emphas…”
BackgroundKetogenic Diet Improves Core Symptoms of Autism in BTBR Mice
Ruskin, D. N., Svedova, J., Cote, J. L., Sandau, U., Rho, J. M., Kawamura, M., Boison, D., & Masino, S. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065021 · Cited by 173
Fuchs, C., Trazzi, S., Torricella, R., Viggiano, R., De Franceschi, M., Amendola, E., Gross, C., Calzà, L., Bartesaghi, R., & Ciani, E. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.006 · Cited by 138
Cited by
Kossoff, E. H., Zupec‐Kania, B. A., Auvin, S., Ballaban‐Gil, K. R., Christina Bergqvist, A. G., Blackford, R., Buchhalter, J. R., Caraballo, R. H., Cross, J. H., Dahlin, M. G., et al. (2018) · Epilepsia Open · doi:10.1002/epi4.12225 · Cited by 768
Symonds, J. D., Zuberi, S. M., Stewart, K., McLellan, A., O‘Regan, M., MacLeod, S., Jollands, A., Joss, S., Kirkpatrick, M., Brunklaus, A., et al. (2019) · Brain · doi:10.1093/brain/awz195 · Cited by 459
Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies
Guerrini, R., Balestrini, S., Wirrell, E. C., & Walker, M. C. (2021) · Neurology · doi:10.1212/wnl.0000000000012744 · Cited by 108
Metadata
- Authors
- Lim, Z., Wong, K., Olson, H. E., Bergin, A. M., Downs, J., & Leonard, H.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2017-06-12
- Volume
- 58
- Issue
- 8
- Pages
- 1415-1422
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2626971719
- Cited by
- 67
- References
- 5
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of the ketogenic diet to manage refractory epilepsy in CDKL 5 disorder: Experience of >100 patients. https://app.cochat.ai/papers/10.1111/epi.13813
- The paper
- Lim, Z., Wong, K., Olson, H. E., Bergin, A. M., Downs, J., & Leonard, H. (2017). Use of the ketogenic diet to manage refractory epilepsy in CDKL 5 disorder: Experience of >100 patients. Epilepsia. https://doi.org/10.1111/epi.13813
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.